The global market for Antibody Development Services was valued at US$ 1527 million in the year 2024 and is projected to reach a revised size of US$ 2664 million by 2031, growing at a CAGR of 8.4% during the forecast period.
Antibody development services refer to specialized services provided by contract research organizations (CROs) or biotechnology companies to support the discovery, engineering, and production of antibodies for various research, diagnostic, therapeutic, and biotechnological applications. These services encompass a wide range of activities aimed at generating specific antibodies against target antigens, optimizing their properties, and producing them in suitable quantities. Antibodies are crucial tools in the fields of immunology, molecular biology, drug development, and diagnostics.
Single-cell RNA sequencing and antibody profiling techniques were increasingly being used to isolate and characterize individual B cells, allowing for the identification of rare and potent antibodies with therapeutic potential.
This report aims to provide a comprehensive presentation of the global market for Antibody Development Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Development Services.
The Antibody Development Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody Development Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Development Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Thermo Fisher Scientific
R&D Systems
Leinco Technologies
Rockland Immunochemicals, Inc. (Rockland)
Bio-Rad
BioGenes
ProteoGenix
Labcorp
Inotiv, Inc.
ProMab Biotechnologies
Kemp Proteins
Synaptic Systems
ARVYS Proteins, Inc.
BBI Solutions
Innovagen AB
BIOTEM
Medimab
OriGene
Abeomics Inc.
RayBiotech
Genscript Biotech Corporation
Sino Biological
Abzena Ltd
Creative Biolabs
Abcam
Antibodies Incorporated
Segment by Type
Monoclonal Antibody Development
Polyclonal Antibody Development
Segment by Application
Medical Industry
Biological Industry
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Development Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Antibody Development Services 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Monoclonal Antibody Development
1.2.3 Polyclonal Antibody Development
1.3 麻豆原创 by Application
1.3.1 Global Antibody Development Services 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Medical Industry
1.3.3 Biological Industry
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody Development Services 麻豆原创 Perspective (2020-2031)
2.2 Global Antibody Development Services Growth Trends by Region
2.2.1 Global Antibody Development Services 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibody Development Services Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Antibody Development Services Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Antibody Development Services 麻豆原创 Dynamics
2.3.1 Antibody Development Services Industry Trends
2.3.2 Antibody Development Services 麻豆原创 Drivers
2.3.3 Antibody Development Services 麻豆原创 Challenges
2.3.4 Antibody Development Services 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody Development Services Players by Revenue
3.1.1 Global Top Antibody Development Services Players by Revenue (2020-2025)
3.1.2 Global Antibody Development Services Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Antibody Development Services 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody Development Services Revenue
3.4 Global Antibody Development Services 麻豆原创 Concentration Ratio
3.4.1 Global Antibody Development Services 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Development Services Revenue in 2024
3.5 Global Key Players of Antibody Development Services Head office and Area Served
3.6 Global Key Players of Antibody Development Services, Product and Application
3.7 Global Key Players of Antibody Development Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody Development Services Breakdown Data by Type
4.1 Global Antibody Development Services Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Antibody Development Services Forecasted 麻豆原创 Size by Type (2026-2031)
5 Antibody Development Services Breakdown Data by Application
5.1 Global Antibody Development Services Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Antibody Development Services Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Antibody Development Services 麻豆原创 Size (2020-2031)
6.2 North America Antibody Development Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibody Development Services 麻豆原创 Size by Country (2020-2025)
6.4 North America Antibody Development Services 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody Development Services 麻豆原创 Size (2020-2031)
7.2 Europe Antibody Development Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibody Development Services 麻豆原创 Size by Country (2020-2025)
7.4 Europe Antibody Development Services 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody Development Services 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Antibody Development Services 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibody Development Services 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Antibody Development Services 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody Development Services 麻豆原创 Size (2020-2031)
9.2 Latin America Antibody Development Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibody Development Services 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Antibody Development Services 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody Development Services 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Antibody Development Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibody Development Services 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Antibody Development Services 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Antibody Development Services Introduction
11.1.4 Thermo Fisher Scientific Revenue in Antibody Development Services Business (2020-2025)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 R&D Systems
11.2.1 R&D Systems Company Details
11.2.2 R&D Systems Business Overview
11.2.3 R&D Systems Antibody Development Services Introduction
11.2.4 R&D Systems Revenue in Antibody Development Services Business (2020-2025)
11.2.5 R&D Systems Recent Development
11.3 Leinco Technologies
11.3.1 Leinco Technologies Company Details
11.3.2 Leinco Technologies Business Overview
11.3.3 Leinco Technologies Antibody Development Services Introduction
11.3.4 Leinco Technologies Revenue in Antibody Development Services Business (2020-2025)
11.3.5 Leinco Technologies Recent Development
11.4 Rockland Immunochemicals, Inc. (Rockland)
11.4.1 Rockland Immunochemicals, Inc. (Rockland) Company Details
11.4.2 Rockland Immunochemicals, Inc. (Rockland) Business Overview
11.4.3 Rockland Immunochemicals, Inc. (Rockland) Antibody Development Services Introduction
11.4.4 Rockland Immunochemicals, Inc. (Rockland) Revenue in Antibody Development Services Business (2020-2025)
11.4.5 Rockland Immunochemicals, Inc. (Rockland) Recent Development
11.5 Bio-Rad
11.5.1 Bio-Rad Company Details
11.5.2 Bio-Rad Business Overview
11.5.3 Bio-Rad Antibody Development Services Introduction
11.5.4 Bio-Rad Revenue in Antibody Development Services Business (2020-2025)
11.5.5 Bio-Rad Recent Development
11.6 BioGenes
11.6.1 BioGenes Company Details
11.6.2 BioGenes Business Overview
11.6.3 BioGenes Antibody Development Services Introduction
11.6.4 BioGenes Revenue in Antibody Development Services Business (2020-2025)
11.6.5 BioGenes Recent Development
11.7 ProteoGenix
11.7.1 ProteoGenix Company Details
11.7.2 ProteoGenix Business Overview
11.7.3 ProteoGenix Antibody Development Services Introduction
11.7.4 ProteoGenix Revenue in Antibody Development Services Business (2020-2025)
11.7.5 ProteoGenix Recent Development
11.8 Labcorp
11.8.1 Labcorp Company Details
11.8.2 Labcorp Business Overview
11.8.3 Labcorp Antibody Development Services Introduction
11.8.4 Labcorp Revenue in Antibody Development Services Business (2020-2025)
11.8.5 Labcorp Recent Development
11.9 Inotiv, Inc.
11.9.1 Inotiv, Inc. Company Details
11.9.2 Inotiv, Inc. Business Overview
11.9.3 Inotiv, Inc. Antibody Development Services Introduction
11.9.4 Inotiv, Inc. Revenue in Antibody Development Services Business (2020-2025)
11.9.5 Inotiv, Inc. Recent Development
11.10 ProMab Biotechnologies
11.10.1 ProMab Biotechnologies Company Details
11.10.2 ProMab Biotechnologies Business Overview
11.10.3 ProMab Biotechnologies Antibody Development Services Introduction
11.10.4 ProMab Biotechnologies Revenue in Antibody Development Services Business (2020-2025)
11.10.5 ProMab Biotechnologies Recent Development
11.11 Kemp Proteins
11.11.1 Kemp Proteins Company Details
11.11.2 Kemp Proteins Business Overview
11.11.3 Kemp Proteins Antibody Development Services Introduction
11.11.4 Kemp Proteins Revenue in Antibody Development Services Business (2020-2025)
11.11.5 Kemp Proteins Recent Development
11.12 Synaptic Systems
11.12.1 Synaptic Systems Company Details
11.12.2 Synaptic Systems Business Overview
11.12.3 Synaptic Systems Antibody Development Services Introduction
11.12.4 Synaptic Systems Revenue in Antibody Development Services Business (2020-2025)
11.12.5 Synaptic Systems Recent Development
11.13 ARVYS Proteins, Inc.
11.13.1 ARVYS Proteins, Inc. Company Details
11.13.2 ARVYS Proteins, Inc. Business Overview
11.13.3 ARVYS Proteins, Inc. Antibody Development Services Introduction
11.13.4 ARVYS Proteins, Inc. Revenue in Antibody Development Services Business (2020-2025)
11.13.5 ARVYS Proteins, Inc. Recent Development
11.14 BBI Solutions
11.14.1 BBI Solutions Company Details
11.14.2 BBI Solutions Business Overview
11.14.3 BBI Solutions Antibody Development Services Introduction
11.14.4 BBI Solutions Revenue in Antibody Development Services Business (2020-2025)
11.14.5 BBI Solutions Recent Development
11.15 Innovagen AB
11.15.1 Innovagen AB Company Details
11.15.2 Innovagen AB Business Overview
11.15.3 Innovagen AB Antibody Development Services Introduction
11.15.4 Innovagen AB Revenue in Antibody Development Services Business (2020-2025)
11.15.5 Innovagen AB Recent Development
11.16 BIOTEM
11.16.1 BIOTEM Company Details
11.16.2 BIOTEM Business Overview
11.16.3 BIOTEM Antibody Development Services Introduction
11.16.4 BIOTEM Revenue in Antibody Development Services Business (2020-2025)
11.16.5 BIOTEM Recent Development
11.17 Medimab
11.17.1 Medimab Company Details
11.17.2 Medimab Business Overview
11.17.3 Medimab Antibody Development Services Introduction
11.17.4 Medimab Revenue in Antibody Development Services Business (2020-2025)
11.17.5 Medimab Recent Development
11.18 OriGene
11.18.1 OriGene Company Details
11.18.2 OriGene Business Overview
11.18.3 OriGene Antibody Development Services Introduction
11.18.4 OriGene Revenue in Antibody Development Services Business (2020-2025)
11.18.5 OriGene Recent Development
11.19 Abeomics Inc.
11.19.1 Abeomics Inc. Company Details
11.19.2 Abeomics Inc. Business Overview
11.19.3 Abeomics Inc. Antibody Development Services Introduction
11.19.4 Abeomics Inc. Revenue in Antibody Development Services Business (2020-2025)
11.19.5 Abeomics Inc. Recent Development
11.20 RayBiotech
11.20.1 RayBiotech Company Details
11.20.2 RayBiotech Business Overview
11.20.3 RayBiotech Antibody Development Services Introduction
11.20.4 RayBiotech Revenue in Antibody Development Services Business (2020-2025)
11.20.5 RayBiotech Recent Development
11.21 Genscript Biotech Corporation
11.21.1 Genscript Biotech Corporation Company Details
11.21.2 Genscript Biotech Corporation Business Overview
11.21.3 Genscript Biotech Corporation Antibody Development Services Introduction
11.21.4 Genscript Biotech Corporation Revenue in Antibody Development Services Business (2020-2025)
11.21.5 Genscript Biotech Corporation Recent Development
11.22 Sino Biological
11.22.1 Sino Biological Company Details
11.22.2 Sino Biological Business Overview
11.22.3 Sino Biological Antibody Development Services Introduction
11.22.4 Sino Biological Revenue in Antibody Development Services Business (2020-2025)
11.22.5 Sino Biological Recent Development
11.23 Abzena Ltd
11.23.1 Abzena Ltd Company Details
11.23.2 Abzena Ltd Business Overview
11.23.3 Abzena Ltd Antibody Development Services Introduction
11.23.4 Abzena Ltd Revenue in Antibody Development Services Business (2020-2025)
11.23.5 Abzena Ltd Recent Development
11.24 Creative Biolabs
11.24.1 Creative Biolabs Company Details
11.24.2 Creative Biolabs Business Overview
11.24.3 Creative Biolabs Antibody Development Services Introduction
11.24.4 Creative Biolabs Revenue in Antibody Development Services Business (2020-2025)
11.24.5 Creative Biolabs Recent Development
11.25 Abcam
11.25.1 Abcam Company Details
11.25.2 Abcam Business Overview
11.25.3 Abcam Antibody Development Services Introduction
11.25.4 Abcam Revenue in Antibody Development Services Business (2020-2025)
11.25.5 Abcam Recent Development
11.26 Antibodies Incorporated
11.26.1 Antibodies Incorporated Company Details
11.26.2 Antibodies Incorporated Business Overview
11.26.3 Antibodies Incorporated Antibody Development Services Introduction
11.26.4 Antibodies Incorporated Revenue in Antibody Development Services Business (2020-2025)
11.26.5 Antibodies Incorporated Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Thermo Fisher Scientific
R&D Systems
Leinco Technologies
Rockland Immunochemicals, Inc. (Rockland)
Bio-Rad
BioGenes
ProteoGenix
Labcorp
Inotiv, Inc.
ProMab Biotechnologies
Kemp Proteins
Synaptic Systems
ARVYS Proteins, Inc.
BBI Solutions
Innovagen AB
BIOTEM
Medimab
OriGene
Abeomics Inc.
RayBiotech
Genscript Biotech Corporation
Sino Biological
Abzena Ltd
Creative Biolabs
Abcam
Antibodies Incorporated
听
听
*If Applicable.
